Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment

Trial Profile

Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPALA
  • Sponsors Mologen
  • Most Recent Events

    • 06 Oct 2019 This trial has been discontiued in Spain, according to European Clinical Trials Database record.
    • 24 Sep 2019 This trial has been completed in Austria, Germany,Estonia according to European Clinical Trials Database.
    • 05 Aug 2019 According to a Mologen media release, the detailed data from this first top line analysis of the this trial will be submitted for presentation at an upcoming international scientific congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top